Here are relevant reports on : cancer-immunotherapy-market
-
Incontinence and Ostomy Care Market by Procedure (Ileostomy, Urostomy, Colostomy), Disease (Cancer, Crohn's Disease, Diarrhea), Product (Adsorbent, Deodorizer, Ostomy Bag, Skin Barrier), Application (Protection, Cleansing) Global Forecasts to 2019
The global incontinence and ostomy care market is estimated to grow at a high rate from 2014 to 2019. The key drivers propelling the growth of global incontinence and ostomy care market include global rise in population of obese and geriatric individuals, development of innovative and personalized products offering greater patient comfort, rising awareness and acceptance related to ostomy care products, and increasing prevalence of target diseases.
- Published: December 2024
- Price: $ 4950
- TOC Available:
-
Pharmacogenomics Market by Product & Service (Kits & Reagents), Technology (Sequencing, PCR, Microarray), Application (Drug Discovery, Clinical Research, Personalized Medicine), Disease Area (Cancer, Neurological, Cardiovascular) - Global Forecast to 2028
The global pharmacogenomics market growth is primed to transition from $3.5 Billion in 2023 to $5.8 Billion by 2028, showcasing a strong CAGR of 10.6%. Additionally, the substantial growth of pharmacogenomics in the past decade can be attributed to an intensified emphasis on translational research for drug discovery and development.
- Published: February 2024
- Price: $ 4950
- TOC Available:
-
Lymphedema Diagnostics Market by Technology (Lymphoscintigraphy, MRI, Near IR Fluorescence Imaging, Ultrasound), Disease Type (Cancer, Inflammatory Diseases, Cardiovascular, Filariasis), End User (Hospitals, Diagnostic Centers) - Global Forecasts to 2024
The Lymphedema Diagnostics Market is expected to grow from USD 24 million in 2019 to USD 35 million by 2024, at a CAGR of 7.4% during the forecast period. The major players operating in the lymphedema diagnostics market are GE Healthcare (US), Philips (Netherlands), and Siemens Healthineers (Germany). Other prominent players in this market include Canon, Inc. (Japan), Shimadzu Corporation (Japan), Stryker Corporation (US), Fluoptics (France), United Imaging Healthcare Co., Ltd. (China), Hitachi, Ltd. (Japan), Esaote, SpA (Italy), Neusoft Corporation (China), Mindray Medical International, Ltd. (China), Mitaka USA, Inc. (US), Curadel, LLC (US), and ImpediMed Ltd. (Australia).
- Published: October 2019
- Price: $ 4950
- TOC Available:
-
Molecular Cytogenetics Market by Product (Kits, Reagents, Probes, Instrument, Software, Services), Technique (FISH, CISH, Comparative Genomic Hybridization (Array-based, Standard)), Application (Cancer, Genetics Disorders) - Global Forecast to 2028
The global molecular cytogenetics market growth is primed to transition from $3.1 billion in 2023 to $4.9 billion by 2029, showcasing a strong CAGR of 9.9%. The development process for cytogenetics products is exceedingly intricate and costly, demanding substantial investments, technical expertise, proficiency in clinical trials, adherence to scientific standards, and robust quality systems.
- Published: January 2024
- Price: $ 4950
- TOC Available:
-
Breast Cancer Liquid Biopsy Market by Circulating Biomarkers, Region, End User, Investments, Market Dynamics, Platform Comparison (NGS, PCR), Competitive Landscape (Acquisition, Mergers, Collaboration, Competitive technology) & Geography
The global breast cancer liquid biopsy market is projected to grow at a CAGR of 23.1%. Factors such as increasing prevalence of breast cancer, increasing preference for noninvasive procedures, initiatives undertaken by government and global health organizations, technological advancements to augment market revenues, rising emphasis on personalized medicine in clinical practice, and increased funding for liquid biopsy R&D are driving the growth of the breast cancer liquid biopsy market. The key players in the global breast cancer liquid biopsy market are QIAGEN N.V. (Netherlands), Roche Diagnostics (US), Bio-Rad Laboratories Inc. (US), Myriad Genetics, Inc. (US), Menarini Silicon Biosystems (Italy), Genomic Health, Inc. (US), Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), Biocept, Inc. (US), Trovagene, Inc. (US), Guardant Health, Inc. (US), RainDance Technologies, Inc. (US), and MDx Health SA (US).
- Published: August 2018
- Price: $ 4950
- TOC Available:
-
Vaccine Adjuvants Market by Product (Emulsions, Pathogen, Saponin, Particulate), Route of administration (Subcutaneous, Intramuscular), Disease Type (Infectious, Cancer), Type ( Human vaccine , Veterinary vaccine) - Global Forecast to 2028
The global vaccine adjuvants market in terms of revenue was estimated to be worth $0.8 billion in 2023 and is poised to reach $1.2 billion by 2028, growing at a CAGR of 6.9% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market.
- Published: September 2023
- Price: $ 4950
- TOC Available:
-
Cell Counting Market by Product (Instruments (Spectrophotometer, Hemocytometer, Flow Cytometer, Hematology Analyzers), Consumables (Reagent, Microplate)), Cancer, Stem Cell Research, End User (Pharmaceutical, Hospital, Research) & Region - Global Forecast to 2025
The global cell counting market growth is primed to transition from $10.4 billion in 2020 to $14.5 billion by 2025, showcasing a strong CAGR of 6.7%. The market growth is largely driven by factors such as growing funding for cell-based research, rising incidence of chronic and infectious diseases, growing biotechnology and biopharmaceutical industries, the development of enhanced solutions and improved image analysis, and the growing use of high-throughput flow cytometry and automated hematology analyzers.
- Published: June 2020
- Price: $ 4950
- TOC Available:
-
Biomarkers Market by Product & Service (Consumable, Software), Type (Safety, Efficacy), Research Area, Technology (NGS, PCR, Mass Spectrometry), Disease (Cancer, Infectious), Application (Diagnostics, Clinical Research) & Region - Global Forecast to 2029
The global biomarkers market growth is primed to transition from USD 57.7 billion in 2024 to USD 93.8 billion by 2029, showcasing a strong CAGR of 10.2%. The major factors driving the growth of this market include the growing importance of companion diagnostics, the increase in the global prevalence of cancer, and the growing importance of biomarkers for rare conditions.
- Published: April 2024
- Price: $ 4950
- TOC Available:
-
Lung Cancer Surgery Market by Instrument ((Clamps, Foreceps, Trocars, Retractors, Scissors), Monitoring & Endoscopic Devices), Procedure (Thoracotomy (Lobectomy, Pneumonectomy, Segmentectomy, Sleeve Resection), MIS), Volume Data & Region - Global Forecast to 2026
The global lung cancer surgery market growth is primed to transition from $5.4 billion in 2020 to $6.7 billion by 2026, showcasing a strong CAGR of 3.8%. Market growth is largely driven by factors such as the technological advancements in lung cancer treatment, the increasing incidence and prevalence of lung cancer, the growing trend of smoking tobacco, the rising geriatric population, the increasing emphasis on early diagnosis and treatment of cancers, and the availability of reimbursement.
- Published: June 2021
- Price: $ 4950
- TOC Available:
-
Home Healthcare Market by Product (Dialysis Equipment, Ventilators, HIV Test Kits, Hearing Aids, Activity Monitors), Service (Skilled Nursing, Infusion Therapy, Palliative Care), Indication (Cancer, Wound Care, Diabetes), & Region - Global Forecast to 2028
The global home healthcare market growth is primed to transition from USD 250 billion in 2023 to USD 383 billion by 2028, showcasing a strong CAGR of 8.9%. The rising demand for cost-effective healthcare delivery due to the increasing healthcare costs and the increase in the geriatric population are the major factors driving the market’s growth.
- Published: January 2024
- Price: $ 4950
- TOC Available:
Records 41 to 50 of 50
